This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Abciximab to tirofiban switch not worth it. Pharmacoecon. Outcomes News 437, 7 (2003). https://doi.org/10.1007/BF03276994
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03276994